Trial Profile
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 09 Apr 2022 The trial has been completed in Spain according to Eudra record.
- 20 Jun 2014 New trial record